/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
With a market cap of $101.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a leading U.S.-based biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it specializes in the discovery, development, manufacturing, and commercialization of transformative therapies, particularly for serious and rare diseases.
Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Vertex Pharmaceuticals fits this criterion perfectly. It holds a commanding lead in cystic fibrosis care, anchored by a portfolio of highly effective, disease-modifying therapies that set the standard in treatment. Beyond this core strength, the company is advancing a diversified pipeline in high-impact areas such as genetic diseases, kidney disorders, type 1 diabetes, and non-opioid pain management, positioning itself for sustained growth well beyond cystic fibrosis.
